ArticleFrontiers in oncology2025
Neoadjuvant chemotherapy, DEB-TACE, and 3D-printed prosthesis for primary pelvic pleomorphic undifferentiated sarcoma: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary leiomyosarcoma of the lumbar soft tissue treated with multimodal therapy, including anlotinib: A case report.Oncology letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleomorphic undifferentiated sarcoma (PUS) is a highly malignant soft tissue sarcoma typically found in the extremities or visceral organs, with primary pelvic cases being exceedingly rare and lacking standardized management strategies. We present the case of an elderly female with primary pelvic PUS who presented with right hip pain and progressive immobility. The tumor was large and involved surrounding tissues, making single-stage en bloc resection unfeasible. A multimodal strategy was implemented, including neoadjuvant chemotherapy combined with anlotinib, followed by drug-eluting bead transarterial chemoembolization (DEB-TACE), and subsequent resection and reconstruction with a 3D-printed pelvic prosthesis were performed. The patient achieved satisfactory functional recovery, and at the 12-month follow-up, there was no evidence of recurrence or metastasis and tumor was judged to have achieved pathological complete remission (pCR).This case demonstrates the feasibility of individualized multimodal therapy for complex pelvic PUS and provides valuable insights for managing this challenging entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.